Keep tabs on your favorite ETFs with a personalized weekly tracker. Create a Watchlist now →
Global X Genomics & Biotechnology ETF - USD (GNOM) belongs to the BioTech & Genomics segment. Virtus LifeSci Biotech Products ETF (BBP) is part of the Tomorrow's Treatments segment. Both ETFs have the same top 3 sector exposures: and Health Care. GNOM is less expensive with a Total Expense Ratio (TER) of 0.5%, versus 0.79% for BBP. GNOM is down -0.99% year-to-date (YTD) with -$2M in YTD flows. BBP performs better with 6.54% YTD performance, and +$4M in YTD flows. Run a side-by-side ETF comparison of GNOM and BBP below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | GNOM BBP | -2.35%+3.49% | -3.29%+9.58% | -0.99%+6.54% | +29.80%+42.80% | -6.02%+83.49% | -51.80%+60.18% |
| Flows | GNOM BBP | -+$4M | -$4M+$16M | -$2M+$4M | -$19M+$19M | -$115M+$19M | +$11M+$9M |
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | GNOM BBP | +23.45%+24.65% | +30.08%+25.47% | +28.53%+23.56% | +33.47%+26.14% |
| Max drawdown | GNOM BBP | -10.89%-7.42% | -22.14%-17.97% | -46.50%-25.54% | -72.17%-38.24% |
| Max drawdown duration | GNOM BBP | 48d32d | 113d106d | 1031d292d | 1714d915d |
GNOM | BBP | |
Last sale 3/12/2026 at 1:30 PM | $43.93 | $81.68 |
| Previous close 03/11/2026 | $45.00 | $84.32 |
| Consolidated volume 03/11/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Create an account to view replication metrics
GNOM | BBP | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
GNOM | BBP | |
|---|---|---|
| Last price | $43.93 | $81.68 |
| 1D performance | -2.38% | -3.13% |
| AuM | $49.36 M | $50.98 M |
| E/R | 0.5% | 0.79% |
GNOM | BBP | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | Global X | VIRTUS Investment Partners |
| Benchmark | Solactive Genomics Index | LifeSci Biotechnology Products Index |
| N° of holdings | 46 | 58 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | April 5, 2019 | December 16, 2014 |
| ESG | No | No |
Total weight of top 15 holdings out of 15
Total weight of top 15 holdings out of 15
Join J.P. Morgan’s Bram Kaplan, Head of Americas Equity Derivatives Strategy and Matt Kaufman from Calamos Investments as they dive into the growing global opportunity in autocallable income—an increasingly dominant strategy within structured products, now available through ETFs.
Accepted for 1 CE Credit
